Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-113 in generalized myasthenia gravis
NL-OMON43317Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Dec 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing ARGX-113 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events and serious adverse events and Safety assessments. Started Dec 2016; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON43317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43317.